Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Processa Pharmaceuticals Inc PCSA

Healthcare Biotechnology
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC... see more

Recent & Breaking News (NDAQ:PCSA)

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

GlobeNewswire October 30, 2024

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

GlobeNewswire October 2, 2024

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

GlobeNewswire September 3, 2024

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

GlobeNewswire August 28, 2024

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

GlobeNewswire August 19, 2024

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

GlobeNewswire July 30, 2024

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

GlobeNewswire July 17, 2024

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

GlobeNewswire June 11, 2024

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

GlobeNewswire May 6, 2024

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

GlobeNewswire April 30, 2024

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

GlobeNewswire April 11, 2024

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

GlobeNewswire March 28, 2024

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 25, 2024

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 21, 2024

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

GlobeNewswire February 14, 2024

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire February 6, 2024

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

GlobeNewswire February 1, 2024

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

GlobeNewswire January 26, 2024

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

GlobeNewswire January 25, 2024

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

GlobeNewswire January 19, 2024